NCT07174141View on ClinicalTrials.gov

Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib)
Interventions
OTHER

Ophthalmological examination

at inclusion, at 3 months and 6 months; OCT-A retina

BIOLOGICAL

Blood sample

Collection of a 2 mL blood sample at inclusion

Trial Locations (1)

Unknown

CHU Dijon Bourgogne, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT07174141 - Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study | Biotech Hunter | Biotech Hunter